Title (en)

PROSTANE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publication

EP 0011591 B1 19820630 (DE)

Application

EP 79710099 A 19791018

Priority

DE 2845770 A 19781019

Abstract (en)

[origin: ES485199A1] Compounds of the formula < IMAGE > wherein R1 is (a) hydrogen, (b) C1-10 alkyl, (c) C1-10 alkyl substituted by halogen C1-4 alkoxy C6-10 aryl C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group di-C1-4-alkylamino or tri-C1-4-alkylammonium, (d) C4-10 cycloalkyl, (e) C4-10 cycloalkyl substituted by C1-4 alkyl, (f) C6-10 aryl, (g) C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S A is -CH2-CH2-, trans-CH=CH- or -C 3BOND C- W is hydroxymethylene, RO-methylene, CH3 or CH3, < IMAGE > wherein OH or OR is in the alpha - or beta -position and R is an in vivo hydrolyzable and physiologically acceptable ether or acyl group which is conventional for modifying OH groups in prostaglandins D and E together are a direct bond, or D is C1-10 alkylene, C1-10 alkenylene or C1-10 alkynylene or one of these groups substituted by fluorine, and E is oxygen, -C 3BOND C- or a direct bond R2 is (a) a C1-10 hydrocarbon aliphatic radical, (b) a C6-10 hydrocarbon aliphatic radical substituted by C6-10 aryl or by C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group (c) C4-10 cycloalkyl, (d) C4-10 cycloalkyl substituted by C1-4 alkyl, (e) C6-10 aryl, (f) C6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C1-4 alkoxy group or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S and R3 is OH or OR and, when R1 is hydrogen, the salts thereof with physiologically compatible bases, are effective as antihypertensive, bronchiodilators, thrombocyte aggregation inhibitors, inter alia.

IPC 1-7

C07C 177/00; C07C 69/732; C07C 59/46; A61K 31/557

IPC 8 full level

A61K 31/557 (2006.01); **A61K 31/5575** (2006.01); **A61K 31/5585** (2006.01); **A61P 7/02** (2006.01); **A61P 25/02** (2006.01); **A61P 43/00** (2006.01); **C07C 45/59** (2006.01); **C07C 45/67** (2006.01); **C07C 45/71** (2006.01); **C07C 51/00** (2006.01); **C07C 51/353** (2006.01); **C07C 59/46** (2006.01); **C07C 62/32** (2006.01); **C07C 67/00** (2006.01); **C07C 67/343** (2006.01); **C07C 69/732** (2006.01); **C07C 401/00** (2006.01); **C07C 405/00** (2006.01); **C07D 309/12** (2006.01); **C07D 317/72** (2006.01); **C07D 319/12** (2006.01)

CPC (source: EP US)

A61K 31/557 (2013.01 - EP US); **A61P 7/02** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 45/59** (2013.01 - EP US); **C07C 45/673** (2013.01 - EP US); **C07C 45/71** (2013.01 - EP US); **C07C 62/32** (2013.01 - EP US); **C07C 405/0083** (2013.01 - EP US); **C07D 317/72** (2013.01 - EP US); **C07D 319/12** (2013.01 - EP US)

Cited by

EP0195379A3; DE4135193C1; EP0041661A3; US5891910A; US6040336A; GB2129427A; EP0721783A4; US5716989A; FR2533917A1; US5405870A; US5489613A; GB2156343A; EP0195668A3; DE3427797A1; DE3448257C2; JPH0649649B2; GB2199031A; GB2199031B; AT397084B; DE3448256C2; GB2156341A; EP0086404A1; EP2065054A1; US6225347B1; WO8600808A1; WO8801867A1; WO8705294A1; EP0086612B1; EP0155901B1; WO9403175A1; WO9114675A1; EP0057660B1; EP0087237B1; EP0098793B1; WO9706806A1; WO9214438A3

Designated contracting state (EPC)

AT BE CH DE FR GB IT LU NL SE

DOCDB simple family (publication)

EP 0011591 A1 19800528; **EP 0011591 B1 19820630**; AT E1283 T1 19820715; AU 5198779 A 19800424; AU 534090 B2 19840105; CA 1181747 A 19850129; CS 219260 B2 19830325; DD 146594 A5 19810218; DD 146594 B3 19890906; DE 2845770 A1 19800430; DE 2963260 D1 19820819; DK 160246 B 19910218; DK 160246 C 19910722; DK 441479 A 19800420; ES 485199 A1 19800516; FI 69056 B 19850830; FI 69056 C 19851210; FI 793263 A 19800420; GR 72247 B 19831005; HU 184926 B 19841128; IE 49085 B1 19850724; IE 791993 L 19800419; IL 58475 A0 19800131; IL 58475 A 19890910; JP S5557559 A 19800428; JP S6312051 B2 19880317; LU 88288 I2 19940504; MX 9203690 A 19920901; NL 930070 I1 19930901; NL 930070 I2 19940103; NO 151318 B 19841210; NO 151318 C 19850320; NO 1995010 I1 19951219; NO 793353 L 19800422; NZ 191827 A 19820525; PH 20359 A 19861204; SU 1003754 A3 19830307; SU 1310390 A1 19870515; US 4692464 A 19870908; YU 253079 A 19830121; YU 41668 B 19871231; ZA 795598 B 19801029

DOCDB simple family (application)

EP 79710099 A 19791018; AT 79710099 T 19791018; AU 5198779 A 19791019; CA 338081 A 19791019; CS 710879 A 19791019; DD 21625979 A 19791016; DE 2845770 A 19781019; DE 2963260 T 19791018; DK 441479 A 19791019; ES 485199 A 19791019; FI 793263 A 19791019; GR 790160293 A 19791007; HU SC000698 A 19791018; IE 199379 A 19791019; IL 5847579 A 19791017; JP 13503779 A 19791019; LU 88288 C 19930609; MX 9203690 A 19920629; NL 930070 C 19930614; NO 1995010 C 19951219; NO 793353 A 19791018; NZ 19182779 A 19791019; PH 23193 A 19791018; SU 2837202 A 19791018; SU 3242701 A 19810212; US 35241182 A 19820226; YU 253079 A 19791018; ZA 795598 A 19791019